Trial Profile
A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 05 Jul 2018 Results published in the Allergy.
- 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
- 17 Apr 2015 New trial record